重大事件
即時報告
8-K
2026-06-02
Cingulate提交8-K表格披露業務最新進展及附件詳情
AI 繁中摘要
Cingulate Inc. (納斯達克代碼：CING) 於2026年6月2日向美國證監會提交了一份8-K表格，報告多項重要事件。📄
本次申報主要項目包括：
- Item 7.01：監管FD披露 (Regulation FD Disclosure)
- Item 8.01：其他事件 (Other Events)
- Item 9.01：財務報表及附件
公司同步提交了附件EX-99.1，通常為新聞稿或投資者簡報，內容可能涉及業務最新進展、臨床試驗更新或合作動態。作為一家專注中樞神經系統疾病治療的製藥企業，Cingulate正處於關鍵開發階段，本次8-K披露的信息對投資者評估公司短期催化劑及長期前景具有潛在影響。📊
該8-K未包含具體財務數字，投資者應仔細查閱附件全文以獲取細節。管理層或於附件中提供業務展望及未來規劃，惟須以官方文件為準。建議投資者密切留意後續公告及相關監管披露。🔍
展開英文正文
EDGAR Filing Documents for 0001493152-26-026760 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001493152-26-026760 Filing Date 2026-06-02 Accepted 2026-06-02 08:10:25 Documents 13 Period of Report 2026-06-02 Items Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K form8-k.htm iXBRL 8-K 44071 2 EX-99.1 ex99-1.htm EX-99.1 17479 Complete submission text file 0001493152-26-026760.txt 276693 Data Files Seq Description Document Type Size 3 XBRL SCHEMA FILE cing-20260602.xsd EX-101.SCH 3760 4 XBRL DEFINITION FILE cing-20260602_def.xml EX-101.DEF 26604 5 XBRL LABEL FILE cing-20260602_lab.xml EX-101.LAB 36654 6 XBRL PRESENTATION FILE cing-20260602_pre.xml EX-101.PRE 25228 18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5186 Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300 Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings) EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-40874 | Film No.: 261053685 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)